- Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
Differences in kidney-specific DPP-4 inhibition by linagliptin and sitagliptin.
Diabetes research and clinical practice (2018-07-22)
Gerd Luippold, Michael Mark, Thomas Klein, Kerstin Amann, Christoph Daniel
PMID30031047
ABSTRAKT
The two dipeptidyl peptidase (DPP)-4 inhibitors, linagliptin and sitagliptin, were shown to exert different binding kinetics in vitro. Twenty-four hours after oral dosing particularly in vivo inhibition of renal-specific DPP-4 activity was more sustained in Sprague Dawley rats after exposure to linagliptin than it was after sitagliptin.
MATERIAŁY
Numer produktu
Marka
Opis produktu